The company focuses on developing disease-modifying therapies for autoimmune and inflammatory diseases by targeting a novel regulatory immune pathway. Their lead program is aimed at treating autoimmune mediated gastro-intestinal disorders. Founded in 2020 and headquartered in Seattle, Washington, Mozart Therapeutics is developing biologics that specifically target a subset of T-lymphocytes to delay the onset and ameliorate autoimmune diseases.